Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 2/2016

01-02-2016 | Retinal Disorders

Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study

Authors: Irini Chatziralli, George Theodossiadis, Efstratios Parikakis, Ioannis Datseris, Panagiotis Theodossiadis

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 2/2016

Login to get access

Abstract

Purpose

To evaluate prospectively the anatomical and functional results after ocriplasmin injection in patients with vitreomacular traction (VMT), or macular hole (MH) combined with VMT, providing the real-life experience of three centers, using spectral domain-optical coherence tomography (SD-OCT).

Methods

Twenty-four patients with VMT (17 with VMT alone and 7 with an MH combined with VMT) were treated with a single ocriplasmin injection and followed-up prospectively at baseline, day 1, 7, 28 and the last examination of the follow-up for each patient (range: 30–127 days). Best-corrected visual acuity (BCVA) and SD-OCT were performed for patient assessment, while various adverse events were recorded and analysed. At baseline, univariate analysis was also performed to examine the potential predictive factors for VMT release.

Results

66.7 % of patients presented VMT release at the end of the follow-up, while 28.6 % exhibited MH closure. Baseline positive predictive factors for VMT release were young age, being female, phakic lens status, increased vitreofoveal angle, V-shaped and loose vitreomacular adhesion, small adhesion area, thin vitreous strands at the adhesion site and absence of an epiretinal membrane. Four new cases of ellipsoid line changes and subretinal fluid development became evident at day 7 compared to baseline. Lamellar macular hole (LMH) in four cases was first noticed at day 28 post injection. Formation of cystoid macular edema (CME) was noticed in three new cases at day 28 compared to baseline.

Conclusions

Our study demonstrated a VMT release rate of 66.7 %. Apart from the known baseline factors that influence VMT release after ocriplasmin injection, the size of the vitreofoveal angle, a V-shaped and loose vitreomacular adhesion, a small adhesion area, and thin vitreous strands at the adhesion site, could additionally affect the outcome of VMT release. In addition, we studied when VMT release and concomitant events occur and for how long the induced complications lasted.
Literature
2.
go back to reference Uchino E, Uemura A, Ohba N (2001) Initial stages of posterior vitreous detachment in healthy eyes of older persons evaluated by optical coherence tomography. Arch Ophthalmol 119:1475–1479PubMedCrossRef Uchino E, Uemura A, Ohba N (2001) Initial stages of posterior vitreous detachment in healthy eyes of older persons evaluated by optical coherence tomography. Arch Ophthalmol 119:1475–1479PubMedCrossRef
3.
4.
go back to reference Girach A, Pakola S (2012) Vitreomacular interface diseases. Pathophysiology, diagnosis and future treatment options. Expert Rev Ophthalmol 7:311–323CrossRef Girach A, Pakola S (2012) Vitreomacular interface diseases. Pathophysiology, diagnosis and future treatment options. Expert Rev Ophthalmol 7:311–323CrossRef
5.
go back to reference Jackson TL, Nicod E, Simpson A, Angelis A, Grimaccia F, Kanavos P (2013) Symptomatic vitreomacular adhesion. Retina 33:1503–1511PubMedCrossRef Jackson TL, Nicod E, Simpson A, Angelis A, Grimaccia F, Kanavos P (2013) Symptomatic vitreomacular adhesion. Retina 33:1503–1511PubMedCrossRef
6.
go back to reference Theodossiadis GP, Chatziralli IP, Sergentanis TN, Datseris I, Theodossiadis PG (2014) Evolution of vitreomacular adhesion to acute vitreofoveal separation with special emphasis on a traction-induced foveal pathology. A prospective study of spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol (in press). doi:10.1007/s00417-014-2826-9 Theodossiadis GP, Chatziralli IP, Sergentanis TN, Datseris I, Theodossiadis PG (2014) Evolution of vitreomacular adhesion to acute vitreofoveal separation with special emphasis on a traction-induced foveal pathology. A prospective study of spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol (in press). doi:10.​1007/​s00417-014-2826-9
7.
go back to reference Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P (2013) The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 120:2611–2619PubMedCrossRef Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P (2013) The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 120:2611–2619PubMedCrossRef
8.
go back to reference Stalmans P, Duker JS, Kaiser PK, Heier JS, Dugel PU, Gandorfer A, Sebag J, Haller JA (2013) Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina 33:2003–2011PubMedCrossRef Stalmans P, Duker JS, Kaiser PK, Heier JS, Dugel PU, Gandorfer A, Sebag J, Haller JA (2013) Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina 33:2003–2011PubMedCrossRef
9.
go back to reference Odrobina D, Michalewska Z, Michalewski J, Dzięgielewski K, Nawrocki J (2011) Long-term evaluation of vitreomacular traction disorder in spectral-domain optical coherence tomography. Retina 31:324–331PubMedCrossRef Odrobina D, Michalewska Z, Michalewski J, Dzięgielewski K, Nawrocki J (2011) Long-term evaluation of vitreomacular traction disorder in spectral-domain optical coherence tomography. Retina 31:324–331PubMedCrossRef
10.
go back to reference Theodossiadis GP, Grigoropoulos VG, Theodoropoulou S, Datseris I, Theodossiadis PG (2014) Spontaneous resolution of vitreomacular traction demonstrated by spectral-domain optical coherence tomography. Am J Ophthalmol 157:842–851PubMedCrossRef Theodossiadis GP, Grigoropoulos VG, Theodoropoulou S, Datseris I, Theodossiadis PG (2014) Spontaneous resolution of vitreomacular traction demonstrated by spectral-domain optical coherence tomography. Am J Ophthalmol 157:842–851PubMedCrossRef
11.
go back to reference Ezra E, Gregor ZJ, Moorfields Macular Hole Study Group (2004) Surgery for idiopathic full-thickness macular hole: two-year results of a randomized clinical trial comparing natural history, vitrectomy, and vitrectomy plus autologous serum: Moorfields Macular Hole Study Group report number 1. Arch Ophthalmol 122:224–236PubMedCrossRef Ezra E, Gregor ZJ, Moorfields Macular Hole Study Group (2004) Surgery for idiopathic full-thickness macular hole: two-year results of a randomized clinical trial comparing natural history, vitrectomy, and vitrectomy plus autologous serum: Moorfields Macular Hole Study Group report number 1. Arch Ophthalmol 122:224–236PubMedCrossRef
12.
go back to reference Hikichi T, Akiba J, Trempe CL (1993) Effect of the vitreous on the prognosis of full-thickness idiopathic macular hole. Am J Ophthalmol 116:273–278PubMedCrossRef Hikichi T, Akiba J, Trempe CL (1993) Effect of the vitreous on the prognosis of full-thickness idiopathic macular hole. Am J Ophthalmol 116:273–278PubMedCrossRef
13.
go back to reference Mester V, Kuhn F (2000) Internal limiting membrane removal in the management of full-thickness macular holes. Am J Ophthalmol 129:769–777PubMedCrossRef Mester V, Kuhn F (2000) Internal limiting membrane removal in the management of full-thickness macular holes. Am J Ophthalmol 129:769–777PubMedCrossRef
14.
go back to reference Kuppermann BD (2012) Ocriplasmin for pharmacologic vitreolysis. Retina 32:225–228CrossRef Kuppermann BD (2012) Ocriplasmin for pharmacologic vitreolysis. Retina 32:225–228CrossRef
15.
go back to reference Syed YY, Dhillon S (2013) Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion. Drugs 73:1617–1625PubMedCrossRef Syed YY, Dhillon S (2013) Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion. Drugs 73:1617–1625PubMedCrossRef
16.
go back to reference Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA, MIVI-TRUST Study Group (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:606–615PubMedCrossRef Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA, MIVI-TRUST Study Group (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:606–615PubMedCrossRef
17.
go back to reference Haller JA, Stalmans P, Benz MS, Gandorfer A, Pakola SJ, Girach A, Kampik A, Jaffe GJ, Toth CA, MIVI-TRUST Study Group (2015) Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology 122:117–122PubMedCrossRef Haller JA, Stalmans P, Benz MS, Gandorfer A, Pakola SJ, Girach A, Kampik A, Jaffe GJ, Toth CA, MIVI-TRUST Study Group (2015) Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology 122:117–122PubMedCrossRef
18.
go back to reference Codenotti M, Iuliano L, Fogliato G, Querques G, Bandello F (2014) A novel spectral-domain optical coherence tomography model to estimate changes in vitreomacular traction syndrome. Graefes Arch Clin Exp Ophthalmol 252:1729–1735PubMedCrossRef Codenotti M, Iuliano L, Fogliato G, Querques G, Bandello F (2014) A novel spectral-domain optical coherence tomography model to estimate changes in vitreomacular traction syndrome. Graefes Arch Clin Exp Ophthalmol 252:1729–1735PubMedCrossRef
19.
go back to reference Warrow DJ, Lai MM, Patel A, Raevis J, Berinstein DM (2015) Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin. Am J Ophthalmol 159:20–30PubMedCrossRef Warrow DJ, Lai MM, Patel A, Raevis J, Berinstein DM (2015) Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin. Am J Ophthalmol 159:20–30PubMedCrossRef
20.
go back to reference Lommatzsch AP, Gutfleisch M, Dietzel M, Heimes B, Spital G, Böhme M, Bornfeld N, Pauleikhoff D (2014) Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin. Klin Monatsbl Augenheilkd 231:909–914PubMedCrossRef Lommatzsch AP, Gutfleisch M, Dietzel M, Heimes B, Spital G, Böhme M, Bornfeld N, Pauleikhoff D (2014) Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin. Klin Monatsbl Augenheilkd 231:909–914PubMedCrossRef
21.
go back to reference Kim BT, Schwartz SG, Smiddy WE, Doshi RR, Kovach JL, Berrocal AM, Moshfeghi AA, Fortun JA (2013) Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion. Ophthalmic Surg Lasers Imaging Retina 44:334–343PubMedCrossRef Kim BT, Schwartz SG, Smiddy WE, Doshi RR, Kovach JL, Berrocal AM, Moshfeghi AA, Fortun JA (2013) Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion. Ophthalmic Surg Lasers Imaging Retina 44:334–343PubMedCrossRef
22.
go back to reference Singh RP, Li A, Bedi R, Srivastava S, Sears JE, Ehlers JP, Schachat AP, Kaiser PK (2014) Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol 98:356–360PubMedCrossRef Singh RP, Li A, Bedi R, Srivastava S, Sears JE, Ehlers JP, Schachat AP, Kaiser PK (2014) Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol 98:356–360PubMedCrossRef
23.
go back to reference Sharma P, Juhn A, Houston SK, Fineman M, Chiang A, Ho A, Regillo C (2015) Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes. Am J Ophthalmol (in press). doi:10.1016/j.ajo.2015.01.034 Sharma P, Juhn A, Houston SK, Fineman M, Chiang A, Ho A, Regillo C (2015) Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes. Am J Ophthalmol (in press). doi:10.​1016/​j.​ajo.​2015.​01.​034
24.
go back to reference de Smet MD, Jonckx B, Vanhove M, van Calster J, Stalmans P, Stassen JM (2012) Pharmacokinetics of ocriplasmin in vitreous. Invest Ophthalmol Vis Sci 53:8208–8213PubMedCrossRef de Smet MD, Jonckx B, Vanhove M, van Calster J, Stalmans P, Stassen JM (2012) Pharmacokinetics of ocriplasmin in vitreous. Invest Ophthalmol Vis Sci 53:8208–8213PubMedCrossRef
25.
go back to reference Stalmans P, Girach A (2013) Vitreous levels of active ocriplasmin following intravitreal injection: results of an ascending exposure trial. Invest Ophthalmol Vis Sci 54:6620–6627PubMedCrossRef Stalmans P, Girach A (2013) Vitreous levels of active ocriplasmin following intravitreal injection: results of an ascending exposure trial. Invest Ophthalmol Vis Sci 54:6620–6627PubMedCrossRef
26.
go back to reference Meyer CH, Rodrigues EB, Mennel S, Schmidt JC, Kroll P (2004) Spontaneous separation of epiretinal membrane in young subjects: personal observations and review of the literature. Graefes Arch Clin Exp Ophthalmol 242:977–985PubMedCrossRef Meyer CH, Rodrigues EB, Mennel S, Schmidt JC, Kroll P (2004) Spontaneous separation of epiretinal membrane in young subjects: personal observations and review of the literature. Graefes Arch Clin Exp Ophthalmol 242:977–985PubMedCrossRef
27.
go back to reference Thanos A, Hernandez-Siman J, Marra KV, Arroyo JG (2014) Reversible vision loss and outer retinal abnormalities after intravitreal ocriplasmin injection. Retin Cases Brief Rep 8:330–332PubMedCrossRef Thanos A, Hernandez-Siman J, Marra KV, Arroyo JG (2014) Reversible vision loss and outer retinal abnormalities after intravitreal ocriplasmin injection. Retin Cases Brief Rep 8:330–332PubMedCrossRef
28.
go back to reference Freund KB, Shah SA, Shah VP (2013) Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin. Eye 27:773–774PubMedPubMedCentralCrossRef Freund KB, Shah SA, Shah VP (2013) Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin. Eye 27:773–774PubMedPubMedCentralCrossRef
30.
go back to reference Itoh Y, Kaiser PK, Singh RP, Srivastava SK, Ehlers JP (2014) Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography. Ophthalmology 121:2506–2507PubMedPubMedCentralCrossRef Itoh Y, Kaiser PK, Singh RP, Srivastava SK, Ehlers JP (2014) Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography. Ophthalmology 121:2506–2507PubMedPubMedCentralCrossRef
31.
32.
go back to reference Casswell E, Fernandez-Sanz G, Mitry D, Luk S, Zakir R (2014) Macular hole progression following ocriplasmin intravitreal injection. Case Rep Ophthalmol Med 2014:403461PubMedPubMedCentral Casswell E, Fernandez-Sanz G, Mitry D, Luk S, Zakir R (2014) Macular hole progression following ocriplasmin intravitreal injection. Case Rep Ophthalmol Med 2014:403461PubMedPubMedCentral
Metadata
Title
Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study
Authors
Irini Chatziralli
George Theodossiadis
Efstratios Parikakis
Ioannis Datseris
Panagiotis Theodossiadis
Publication date
01-02-2016
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 2/2016
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-015-3031-1

Other articles of this Issue 2/2016

Graefe's Archive for Clinical and Experimental Ophthalmology 2/2016 Go to the issue